Literature DB >> 9380435

A novel mitochondrial G8313A mutation associated with prominent initial gastrointestinal symptoms and progressive encephaloneuropathy.

A Verma1, D A Piccoli, E Bonilla, G T Berry, S DiMauro, C T Moraes.   

Abstract

We describe a childhood mitochondrial disorder in which the clinical symptoms began and remained confined to the gastrointestinal (GI) system during the first 4 y. Seizures heralded the onset of progressive encephalopathy at age 7. Peripheral neuropathy, retinitis pigmentosa, and neural deafness developed subsequently. Laboratory investigations disclosed elevated levels of plasma lactate, and a muscle biopsy revealed ragged red fibers lacking cytochrome c oxidase activity and diminished levels of respiratory chain enzyme complexes. Molecular genetic tests failed to show any of the previously reported pathogenic mitochondrial DNA (mtDNA) mutations. We therefore screened the whole mitochondrial genome by coupling restriction digestions with single-strand conformational polymorphism (SSCP) patterns. We identified a unique SSCP in the segment that encompassed the tRNA(Lys) gene, and direct sequencing of this segment revealed a G-->A transition at an evolutionarily conserved nucleotide at mtDNA position 8313. This G8313A transition was heteroplasmic in muscle and fibroblasts of the patient, but was absent in the white blood cells and platelets from his maternal relatives. This report illustrates how GI symptoms can be the initial manifestation in a mitochondrial disorder and suggests that mitochondrial dysfunction should be considered in differentials of unexplained chronic GI symptoms, especially when lactic acidosis or other unrelated clinical signs or symptoms are present.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9380435     DOI: 10.1203/00006450-199710000-00005

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

Review 1.  Clinical mitochondrial genetics.

Authors:  P F Chinnery; N Howell; R M Andrews; D M Turnbull
Journal:  J Med Genet       Date:  1999-06       Impact factor: 6.318

Review 2.  Multisystem manifestations of mitochondrial disorders.

Authors:  Stefano Di Donato
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

Review 3.  Motility disorders of the gastrointestinal tract.

Authors:  Narayanan Venkatasubramani; Manu R Sood
Journal:  Indian J Pediatr       Date:  2006-10       Impact factor: 1.967

4.  Association of mitochondrial DNA content, heteroplasmies and inter-generational transmission with autism.

Authors:  Yiqin Wang; Xiaoxian Guo; Xiumei Hong; Guoying Wang; Colleen Pearson; Barry Zuckerman; Andrew G Clark; Kimberly O O'Brien; Xiaobin Wang; Zhenglong Gu
Journal:  Nat Commun       Date:  2022-07-01       Impact factor: 17.694

5.  Decreased mitochondrial tRNALys steady-state levels and aminoacylation are associated with the pathogenic G8313A mitochondrial DNA mutation.

Authors:  Sandra R Bacman; David P Atencio; Carlos T Moraes
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 6.  Gastrointestinal and hepatic manifestations of mitochondrial disorders.

Authors:  Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2013-05-15       Impact factor: 4.982

7.  Heteroplasmic mutation in the anticodon-stem of mitochondrial tRNA(Val) causing MNGIE-like gastrointestinal dysmotility and cachexia.

Authors:  Rita Horváth; Andreas Bender; Angela Abicht; Elke Holinski-Feder; Birgit Czermin; Tobias Trips; Peter Schneiderat; Hanns Lochmüller; Thomas Klopstock
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

Review 8.  Mitochondrial Neurogastrointestinal Encephalomyopathy: Into the Fourth Decade, What We Have Learned So Far.

Authors:  Dario Pacitti; Michelle Levene; Caterina Garone; Niranjanan Nirmalananthan; Bridget E Bax
Journal:  Front Genet       Date:  2018-12-21       Impact factor: 4.599

9.  Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination.

Authors:  Yi Shiau Ng; Catherine Feeney; Andrew M Schaefer; Carol Ellen Holmes; Paula Hynd; Charlotte L Alston; John P Grady; Mark Roberts; Mellisa Maguire; Alexandra Bright; Robert W Taylor; Yan Yiannakou; Robert McFarland; Doug M Turnbull; Gráinne S Gorman
Journal:  Ann Neurol       Date:  2016-09-19       Impact factor: 10.422

10.  De novo mtDNA point mutations are common and have a low recurrence risk.

Authors:  Suzanne C E H Sallevelt; Christine E M de Die-Smulders; Alexandra T M Hendrickx; Debby M E I Hellebrekers; Irenaeus F M de Coo; Charlotte L Alston; Charlotte Knowles; Robert W Taylor; Robert McFarland; Hubert J M Smeets
Journal:  J Med Genet       Date:  2016-07-22       Impact factor: 6.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.